Patient-Reported Experiences during and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study

被引：2
|
作者：
Eliason, Laurie
Correll, Julia
Martin, Mona
Cardellino, Anna
Opalinska, Joanna
Piontek, Trisha
Gorsh, Boris
Sapra, Sandhya
Popat, Rakesh
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-139395
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study
    Cardellino, Anna
    Correll, Julia R.
    Martin, Mona
    Gorsh, Boris
    Sapra, Sandhya
    Popat, Rakesh
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [2] DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Popat, Rakesh
    Lonial, Sagar
    Voorhees, Peter M.
    Degli Esposti, Simona
    Gupta, Ira
    Opalinska, Joanna
    Sapra, Sandhya
    Gorsh, Boris
    He, Zangdong
    Kleinman, David M.
    Schaumberg, Debra
    Loubert, Angely
    Meunier, Juliette
    Regnault, Antoine
    Eliason, Laurie
    BLOOD, 2020, 136
  • [3] Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)
    Popat, Rakesh
    Kazantzi, Aikaterini
    Farooq, Asim
    Thulasi, Praneetha
    Lonial, Sagar
    Jakubowiak, Andrzej
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Opalinska, Joanna
    Baron, January
    Piontek, Trisha
    Byrne, Julie
    Womersley, Lynsey
    Gupta, Ira
    Esposti, Simona Degli
    BLOOD, 2020, 136
  • [4] Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Nooka, Ajay
    Lee, Hans C.
    Badros, Ashraf Z.
    Voorhees, Peter
    Hultcrantz, Malin
    Karlin, Lionel
    Arnulf, Bertrand
    Richardson, Paul G.
    Zhi, Eric
    Baron, January
    Piontek, Trisha
    Lewis, Eric
    Opalinska, Joanna
    Gupta, Ira
    Cohen, Adam D.
    Lonial, Sagar
    BLOOD, 2020, 136
  • [5] DREAMM-2: Single-agent belantamab mafodotin (belamaf; GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) - outcomes by prior therapies
    Weisel, K.
    Lonial, S.
    Lee, H.
    Badros, A.
    Trudel, S.
    Nooka, A.
    Chari, A.
    Abdallah, A-O
    Callander, N.
    Sborov, D.
    Suvannasankha, A.
    Vorhees, P.
    Opalinska, J.
    Hoos, A.
    Zhi, E.
    Baron, J.
    Piontek, T.
    Jewell, R.
    Gupta, I
    Cohen, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 109 - 110
  • [6] Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM)
    Lonial, Sagar
    Nooka, Ajay K.
    Thulasi, Praneetha
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Callander, Natalie S.
    Sborov, Douglas
    Zaugg, Brian E.
    Popat, Rakesh
    Degli Esposti, Simona
    Baron, January
    Doherty, Allison
    Lewis, Eric
    Opalinska, Joanna
    Paka, Prani
    Piontek, Trisha
    Gupta, Ira
    Farooq, Asim V.
    Jakubowiak, Andrzej
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S419 - S419
  • [7] A real-world observational study of belantamab mafodotin (belamaf) as a treatment for relapsed/refractory multiple myeloma (RRMM)
    Cavo, Michele
    Delforge, Michel
    Dimopoulos, Meletios
    Escalante, Fernando
    Hultcrantz, Malin
    Kleinman, David
    Lee, Hans
    Vij, Ravi
    Kotowsky, Nirali
    Camadoo-O'Byrne, Leena
    Bitetti, Jacopo
    D'Estrube, Tim
    Fry, Mark
    Vossen, Carla
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S166 - S167
  • [8] Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study
    Hultcrantz, Malin
    Kleinman, David
    Vij, Ravi
    Escalante, Fernando
    Kotowsky, Nirali
    Bitetti, Jacopo
    Mackay, Christine
    Boytsov, Natalie
    Camadoo-O'Byrne, Leena
    Germain, Guillaume
    Duh, Mei Sheng
    Laliberte, Francois
    Mahendran, Malena
    Urosevic, Ana
    Lee, Hans C.
    BLOOD, 2022, 140 : 10124 - 10126
  • [9] Characterization of ocular adverse events in patients receiving belantamab mafodotin (belamaf) for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory multiple myeloma (RRMM)
    Trautmann-Grill, K.
    Lonial, S.
    Nooka, A. K.
    Thulasi, P.
    Badros, A. Z.
    Jeng, B. H.
    Callander, N. S.
    Sborov, D.
    Zaugg, B. E.
    Popat, R.
    Degli, Esposti S.
    Baron, J.
    Doherty, A.
    Lewis, E.
    Opalinska, J.
    Paka, P.
    Piontek, T.
    Gupta, I
    Farooq, A., V
    Jakubowiak, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 181 - 181
  • [10] Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexamethasone (Pd) in the DREAMM-3 Study
    Hungria, Vania
    Weisel, Katja
    Currie, Brooke
    Perera, Sue
    Sule, Neal
    He, Wei
    Davy, Katherine
    McKeown, Astrid
    Sapra, Sandhya
    Nelsen, Linda
    Li, Mary
    Barale, Sophie
    Boyle, Julia
    McPoyle, Kaytlyn
    Dimopoulos, Meletios Athanasios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S505 - S505
12345